Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight.
Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight.
复制标题
DOI：
10.1097/mpg.0000000000001096
复制
发表时间：
2016-06
影响因子：
2.9
通讯作者：
Vos MB
中科院分区：
文献类型：
--
作者：
Holzberg JR;Jin R;Le NA;Ziegler TR;Brunt EM;McClain CJ;Konomi JV;Arteel GE;Vos MB
研究PAI-1（一种与心血管疾病风险密切相关的急性期蛋白）与超重和肥胖大范围肝脂肪变性儿童的肥胖、胰岛素抵抗和炎症之间的关系。在39名超重或肥胖儿童的前瞻性队列中测量血浆PAI-1水平，这些儿童接受了全面的人体测量评估和代谢测量。采用磁共振波谱法对肝脂肪变性进行量化，并根据正常肝脂肪变性（<5%）、低肝脂肪变性（≥5-10%）和高肝脂肪变性（>10%）分为3组。在超重和肥胖儿童中，血浆PAI-1水平在肝脂肪变性严重程度中显著升高，且这种关联与BMI z-score、内脏脂肪、胰岛素抵抗和炎症标志物无关（p < 0.05）。儿童肝脂肪变性与循环PAI-1水平呈正相关，与BMI、胰岛素抵抗和炎症标志物无关。需要进一步的研究来阐明PAI-1作为儿科NAFLD治疗靶点的潜在作用。
To examine the association between PAI-1, an acute phase protein strongly associated with cardiovascular disease risk, and adiposity, insulin resistance, and inflammation among overweight and obese children with a wide range of hepatic steatosis. Plasma PAI-1 levels were measured in a prospectively recruited cohort of 39 overweight or obese children who underwent comprehensive anthropometric assessment and metabolic measurements. Hepatic steatosis was quantified using magnetic resonance spectroscopy and participants were divided into 3 groups based on whether they had normal hepatic steatosis (<5%), low hepatic steatosis (≥5–10%) and high hepatic steatosis (>10%). Plasma PAI-1 levels significantly increased across the severity of hepatic steatosis in overweight and obese children, and this association was independent of BMI z-score, visceral fat, insulin resistance, and inflammatory markers (p < 0.05). Hepatic steatosis in children is positively associated with circulating levels of PAI-1 independent of BMI, insulin resistance, and inflammatory markers. Further studies are needed to clarify the potential role of PAI-1 as a therapeutic target in pediatric NAFLD.